Levofloxacin is NOT absolutely contraindicated in G6PD deficiency, but should be used with caution
Levofloxacin can be prescribed to patients with G6PD deficiency with appropriate monitoring, as the risk of hemolytic anemia is low to medium based on current evidence. The FDA drug label does not list G6PD deficiency as a contraindication 1, and recent clinical data support its safe use in this population.
Evidence-Based Risk Assessment
Guideline Recommendations
The most recent and authoritative guidance comes from the 2023 CPIC (Clinical Pharmacogenetics Implementation Consortium) guideline 2, which systematically reviewed medications in G6PD deficiency and classified levofloxacin as medium risk - meaning it should be used with caution rather than avoided entirely. This represents a significant departure from older, more conservative warnings.
The 2017 British Thoracic Society guidelines acknowledge that moxifloxacin (a related fluoroquinolone) carries a "risk of haemolytic reactions when treated with quinolones" in G6PD deficiency 3, but this is listed as a caution rather than absolute contraindication.
Real-World Clinical Evidence
The strongest clinical evidence comes from a 2017 prospective study 4 of 242 blood cancer patients (59 with G6PD deficiency) receiving 628 intensive chemotherapy courses with fluoroquinolone prophylaxis. Zero episodes of acute hemolytic anemia occurred in the G6PD-deficient cohort, demonstrating safety even in this high-risk, heavily treated population.
A 2024 real-world study from Israel 5 examined 31,962 G6PD-deficient patients and found that among 71 cases of major hemolysis requiring hospitalization, only 3 (4.2%) were potentially medication-related, and none were definitively linked to fluoroquinolones. Hundreds to thousands of G6PD-deficient patients safely received ciprofloxacin and ofloxacin.
Contrast with High-Risk Medications
For comparison, rasburicase is explicitly contraindicated in G6PD deficiency 6, as are primaquine (beyond 5 days) 7 and dapsone 8. These represent true contraindications where hemolysis risk is well-documented and severe.
Clinical Approach
When to Use Levofloxacin in G6PD Deficiency
Screen for G6PD deficiency before prescribing if patient has predisposing ethnic background (African, Mediterranean, Southeast Asian descent) 9
Proceed with levofloxacin if clinically indicated, particularly for:
- Drug-resistant tuberculosis (dose adjustment needed in renal disease: 750-1000 mg three times weekly if CrCl <30 mL/min) 10
- Serious infections where alternative agents are inadequate
Monitor during therapy:
- Baseline complete blood count
- Monitor hemoglobin/hematocrit during treatment
- Counsel patient to report dark urine, jaundice, or fatigue immediately
Key Caveats
- Variant-specific risk: Different G6PD variants carry different hemolysis susceptibility 11. Mediterranean variants (Gdmed) pose higher risk than African variants (GdA-) 9
- Dose-dependent risk: Hemolysis risk is almost always dose-related 11
- Limited data: Most safety data comes from other fluoroquinolones (ciprofloxacin, ofloxacin); levofloxacin-specific data is sparse 12
Avoid These High-Risk Medications Instead
In G6PD-deficient patients, prioritize avoiding:
- Rasburicase (absolute contraindication)
- Primaquine >5 days
- Dapsone
- Sulfonamides (though recent data suggests lower risk than historically believed 5)
- Nitrofurantoin (though recent safety review suggests 200 mg daily for 3-5 days may be acceptable 13)
Bottom Line
Levofloxacin is not contraindicated in G6PD deficiency 1. The 2023 CPIC guideline classifies it as medium-risk 2, and robust real-world evidence demonstrates safe use 4, 5. Use with baseline screening, patient counseling about hemolysis symptoms, and CBC monitoring during therapy. Reserve absolute avoidance for truly contraindicated medications like rasburicase.